ORPHAZYME RECEIVES ORPHAN DRUG DESIGNATION TO ARIMOCLOMOL FOR INCLUSION BODY MYOSITIS FROM THE U.S. FDA

Source :: Thomson Reuters ONE. November 7, 2017
Publication Year :: 2017
Abstract: (GLOBE NEWSWIRE via COMTEX) -- Orphazyme A/S Ole Maaloes Vej 3 DK-2200 Copenhagen N www.orphazyme.com Company Registration No. 32266355 7 November 2017 Orphazyme A/S ('Orphazyme' or the 'Company'), a Danish [...]

Subjects :: United States. Food and Drug Administration
International Business Machines Corp. -- Product development
Myositis -- Drug therapy
Orphan drugs -- Product development
Computer industry -- Product development
Microcomputer industry
Computer industry
Business, international

Tools